What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially report Abbott Laboratories' financial results for the second quarter of 2018. It also highlights the company's use of non-GAAP financial measures in its earnings release.

Why does Abbott use non-GAAP financial measures?

Abbott uses non-GAAP financial measures to offer investors a clearer understanding of its ongoing business performance. These measures exclude certain unusual or unpredictable items, such as expenses related to acquisitions, restructuring, and gains from asset sales, which management believes are not reflective of core operational results.

Are the non-GAAP results presented in the filing a substitute for GAAP results?

No, Abbott explicitly cautions investors that non-GAAP financial measures should be considered in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP. Investors should review both sets of figures for a complete picture.

What specific items are excluded in Abbott's non-GAAP reporting for Q2 2018?

The filing mentions that non-GAAP measures exclude items such as expenses primarily associated with acquisitions and restructuring actions, charges related to cost reduction initiatives, the recognition of a gain associated with the sale of the Medical Optics business, and intangible amortization expense.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on July 18, 2018, to report its second-quarter 2018 financial results. The filing primarily references a press release (Exhibit 99.1) that details these results and discusses the company's use of non-GAAP financial measures. These non-GAAP measures are presented to provide investors with a clearer view of ongoing operational performance by excluding items such as acquisition-related expenses, restructuring costs, and gains from divestitures, similar to how management internally assesses performance. Investors should note that while Abbott's management believes these non-GAAP figures offer valuable insights into operational trends, they are not a substitute for GAAP (Generally Accepted Accounting Principles) measures. The company encourages a comprehensive review of both GAAP and non-GAAP financial information when evaluating its performance. The filing also confirms the CFO, Brian B. Yoor, has signed off on the report.

Key Highlights

1Abbott Laboratories announced its second-quarter 2018 financial results on July 18, 2018.
2The 8-K filing incorporates a press release (Exhibit 99.1) containing the detailed financial results.
3Abbott utilized non-GAAP financial measures in its reporting for Q2 2018.
4Non-GAAP measures were adjusted to exclude specified items like acquisition and restructuring costs, and divestiture gains.
5The company aims to provide greater visibility into ongoing business performance through these non-GAAP adjustments.
6Abbott's management uses these non-GAAP measures for internal performance assessment.
7Investors are advised to consider non-GAAP measures in conjunction with, not as a replacement for, GAAP financial measures.

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 18, 2018)

Summary

Key Highlights

Frequently Asked Questions